Earnings release
Page 1
Investors - Trulieve Trulieve Reports Third Quarter 2026 Results Third quarter revenue of $230 million, with 64% gross marginCash flow from operations of $183 million and free cash flow of $120 million* in first nine months of 2026Received final DEA registrations pursuant to final order rescheduling state licensed medical marijuana to Schedule III under the Controlled Substances Act TALLAHASSEE, Fla., Nov. 5, 2026 /PRNewswire/ -- Trulieve Cannabis Corp. (NYSE: TRLV) ("Trulieve" or "the Company"), aleading and top-performing medical cannabis company in the U.S., today announced its results for the quarter endedSeptember 30, 2026. Results are reported in accordance with U.S. Generally Accepted Accounting Principles (GAAP), unlessotherwise indicated. Numbers may not sum perfectly due to rounding. Q3 2026 Financial and Operational Highlights* Revenue of $230 million, with 95% of revenue from retail sales.Achieved gross margin of 64%, with gross profit of $148 million.Reported positive net income attributable to common shareholders of $1 million. Adjusted net income of $18 million* excludes non-recurring charges, asset impairments, disposals, and unconsolidatedentity.Achieved adjusted EBITDA of $89 million*, or 39% of revenue.Generated cash flow from operations of $74 million and free cash flow of $45 million*.Cash at quarter end was $327 million.Realized seven-fold increase in traffic in Georgia following medical cannabis program expansion on July 1 with new product launches including Modern Flower and Roll One.Completed corporate domestication to Delaware from British Columbia.Rang The Closing Bell at the New York Stock Exchange to commemorate NYSE listing.Added to the S&P Total Market Index (TMI), S&P Completion Index (CI) and Morningstar Total Stock Market Index.Closed perpetual royalty free license for Alien Labs and Connected branded cannabis products in Florida and Texas that includes genetics, trademarks, and proprietary know-how and a right of firstrefusal for exclusive licensing rights in additional expansion markets.Opened two dispensaries in Marco Island, Florida, and Dunwoody, Georgia. *See "Non-GAAP Financial Measures" below for additional information and a reconciliation to GAAP for Non-GAAP metrics. Recent Developments Received final registrations from the Drug Enforcement Agency for state licensed medical marijuana dispensaries as part of federal regulatory framework for qualified medical marijuana businessesunder the Controlled Substances Act.Repaid $65 million mortgage notes payable ahead of maturity in 2028 secured by cultivation site in Jefferson County, Florida to reduce leverage and interest expense.Currently operate 208 retail dispensaries and 3.5 million square feet of cultivation and processing capacity in the United States. Management Commentary "State licensed medical marijuana rescheduling unlocked major milestones including DEA registration, removal of 280E tax, anduplisting to the NYSE," said Kim Rivers, Trulieve CEO. "Third quarter results demonstrate the strength of our medical cannabisplatform underscored by revenue, margins, and cash generation. With meaningful growth expansion opportunities in Georgia andTexas, we are in the early stages of an accelerated growth cycle." Financial Highlights* Third quarter 2026 results include only Trulieve medical operations. Prior periods include consolidated results including Harvestmixed medical and adult use operations. Results of Operations For the Three Months Ended For the Nine Months Ende (Figures in millions exceptper share data) September30, 2026 September30, 2025 %Better /(Worse) June 30,2026† %Better /(Worse)September30, 2026 September30, 2025 %Bett(WoRevenue $ 230 $ 288 (20 %) $ 271 (15 %) $ 788 $ 888 (11 Gross profit $ 148 $ 170 (13 %) $ 162 (9 %) $ 480 $ 536 (10 Gross margin % 64 % 59 % 60 % 61 % 60 %Operating expenses $ 106 $ 128 17 %$ 533 80 %$ 773 $ 408 (89 Operating expenses % 46 % 44 % 197 % 98 % 46 %Net income (loss)** $ 1 $ (27) NMF $ (406) NMF $ (403) $ (73) NMNet income (loss) continuing operations $ 1 $ (24) NMF $ (405) NMF $ (401) $ (72) NMAdjusted net income (loss) $ 18 $ (12) NMF $ 20 (12 %) $ 59 $ (24) NMDiluted shares outstanding 201 191 193 193 191Diluted EPS continuing operations $ 0.00 $ (0.11) NMF $(2.10) NMF $ (2.08) $ (0.35) NMAdjusted Diluted EPS $ 0.09 $ (0.07) NMF $ 0.11 (15 %) $ 0.30 $ (0.12) NMAdjusted EBITDA $ 89 $ 103 (13 %) $ 98 (9 %) $ 288 $ 322 (11 Adjusted EBITDA Margin % 39 % 36 % 36 % 36 % 36 % NMF - No Meaningful Figure†Q2:26 reported results reflect the deconsolidation of Harvest mixed medical and adult use operations on June 3, 2026. *See "Non-GAAP Financial Measures" below for additional information and a reconciliation to GAAP for Non-GAAP metrics.**Net income (loss) attributable to common shareholders which excludes non-controlling interest.
Page 2
Conference Call The Company will host a conference call and live audio webcast on November 5, 2026, at 8:30 A.M. Eastern time, to discuss itsthird quarter 2026 financial results. Interested parties can join the conference call by dialing in as directed below. Please dial in15 minutes prior to the call. North American toll free: 1-844-824-3830 Passcode: 8639220International: 1-412-542-4136 Passcode: 8639220 A live audio webcast of the conference call will be available at:Trulieve Third Quarter 2026 Results Call A powerpoint presentation and archived replay of the webcast will be available at:https://investors.trulieve.com/events The Company's Form 10-Q for the quarter ended September 30, 2026 will be available on the SEC's website orat https://investors.trulieve.com/quarterly-results. The Company's Management's Discussion and Analysis for the period and theaccompanying financial statements and notes will be available under the Company's profile on https://www.sedarplus.ca and onits website at https://investors.trulieve.com/quarterly-results. This news release is not in any way a substitute for reading thosefinancial statements, including the notes to the financial statements. Trulieve Cannabis Corp.Condensed Consolidated Balance Sheets (Unaudited)(in millions, except for share data) September 30,2026 December 31,2025ASSETSCurrent Assets:Cash and cash equivalents $ 326.7 $ 255.5Accounts receivable, net 3.8 10.5Inventories 190.8 242.3Income tax receivable 0.5 8.5Prepaid expenses 17.5 18.3Other current assets 2.3 26.7Management services agreement receivable, related party 21.3 —Assets associated with discontinued operations — 0.9Total current assets 562.8 562.7Property and equipment, net 592.9 670.4Right of use assets - operating, net 90.0 108.3Right of use assets - finance, net 55.7 60.0Intangible assets, net 335.0 798.4Goodwill 325.6 483.9Investment in Harvest 146.1 —Other assets 10.0 10.5Long-term assets associated with discontinued operations — 1.9TOTAL ASSETS $ 2,118.2 $ 2,696.1LIABILITIESCurrent Liabilities:Accounts payable and accrued liabilities $ 68.2 $ 82.7Deferred revenue 5.9 9.6Notes payable - current portion 4.2 4.1Operating lease liabilities - current portion 11.9 13.0Finance lease liabilities - current portion 10.7 10.7Construction finance liabilities - current portion 0.7 2.4Contingencies 0.3 0.8Liabilities associated with discontinued operations — 3.7Total current liabilities 102.0 126.9Long-Term Liabilities:Notes payable, net 88.7 90.8Private placement notes, net 196.0 136.7Operating lease liabilities 89.3 107.9Finance lease liabilities 60.5 64.1Construction finance liabilities 120.2 133.8Deferred tax liabilities 55.4 178.0
Page 3
Uncertain tax position liabilities 625.4 668.4Other long-term liabilities 9.3 11.4Long-term liabilities associated with discontinued operations — 34.9TOTAL LIABILITIES $ 1,346.7 $ 1,553.1EQUITYCommon shares, no par value; unlimited shares authorized; None issued andoutstanding as of September 30, 2026 and 169,313,023 shares issued andoutstanding as of December 31, 2025 $ — $ —Preferred stock, $0.0001 par value; 1,000,000,000 shares authorized; noneissued and outstanding as of September 30, 2026 and December 31, 2025 — —Class A subordinate voting common stock, $0.0001 par value per share;5,000,000,000 shares authorized; 170,347,610 shares issued and outstanding asof September 30, 2026 and none issued and outstanding as of December 31,2025 0.0 —Class B multiple voting common stock, $0.0001 par value per share; 300,000shares authorized; 224,064 shares issued and outstanding as of September 30,2026 and none issued and outstanding as of December 31, 2025 — —Additional paid-in-capital 2,088.0 2,073.4Accumulated deficit (1,314.8) (912.1)Non-controlling interest (1.7) (18.2)TOTAL EQUITY 771.5 1,143.0TOTAL LIABILITIES AND EQUITY $ 2,118.2 $ 2,696.1 Trulieve Cannabis Corp.Condensed Consolidated Statements of Operations (Unaudited)(in millions, except for per share data)Three Months EndedSeptember 30, Nine Months EndedSeptember 30,2026 2025 2026 2025Revenue $ 230.2 $ 288.2 $ 787.9 $ 888.Cost of goods sold 82.2 118.3 307.5 352.Gross profit 148.0 169.9 480.4 536.Expenses:Selling, general, and administrative 87.8 99.0 294.5 318.Depreciation and amortization 17.7 29.5 73.2 88.(Gain) loss on disposal or impairment of assets — (0.9) 1.7 0.Loss on deconsolidation transaction — — 403.3 —Total expenses 105.5 127.6 772.7 407.Income (loss) from operations 42.5 42.2 (292.3) 128.Other income (expense):Interest expense, net (12.0) (16.1) (38.1) (48.8Interest income 2.8 4.4 8.6 11.Equity in net loss of Harvest (6.4) — (9.7) —Other income (expense), net 0.1 (1.2) 0.4 (2.0Total other expense, net (15.5) (12.9) (38.8) (39.7Income (loss) before provision for income taxes 27.0 29.3 (331.2) 88.Provision for income taxes 26.3 53.0 70.1 160.Net income (loss) from continuing operations 0.8 (23.7) (401.2) (71.7Net loss from discontinued operations, net of tax benefit (provision) of $0, $0,$597, and $(441) respectively, attributable to common shareholders — (5.0) (1.8) (7.0Net income (loss) 0.8 (28.8) (403.0) (78.7Less: net loss attributable to non-controlling interest from continuing operations (0.1) (1.9) (0.3) (5.2Net income (loss) attributable to common shareholders $ 0.9 $ (26.8) $ (402.7) $ (73.5 Earnings Per ShareNet income (loss) per share - Continuing operations:Basic $ 0.00 $ (0.11) $ (2.08) $ (0.35Diluted $ 0.00 $ (0.11) $ (2.08) $ (0.35Net loss per share - Discontinued operations:Basic and diluted $ —$ (0.03) $ (0.01) $ (0.04Net income (loss) per share attributable to common shareholders:
Page 4
Basic $ 0.00 $ (0.14) $ (2.09) $ (0.39Diluted $ 0.00 $ (0.14) $ (2.09) $ (0.39Weighted average number of common shares used in computing net income (loss)per share:Basic 192.9 191.2 192.7 191.Diluted 200.6 191.2 192.7 191. Trulieve Cannabis Corp.Condensed Consolidated Statements of Cash Flows (Unaudited)(in millions) Three Months EndedSeptember 30, Nine Months EndedSeptember 30,2026 2025 2026 2025Cash flows from operating activitiesNet income (loss) $ 0.8 $ (28.8) $ (403.0) $ (78.7)Adjustments to reconcile net income (loss) to net cash provided byoperating activities:Depreciation and amortization 17.7 29.5 73.2 88.2Depreciation included in cost of goods sold 12.3 13.9 39.7 41.5Loss on deconsolidation transaction — — 403.3 —Equity in net loss of Harvest 6.4 — 9.7 —Impairment and disposal of long-lived assets, net of recoveries — 2.6 1.7 2.5Gain from disposal of discontinued operations — — — —Share-based compensation 5.9 5.8 17.0 16.5Deferred income taxes (1.9) (4.7) (20.9) (14.7)Other non-cash changes 3.1 3.7 9.8 16.0Changes in operating assets and liabilities:Inventories (4.0) (1.8) 2.0 (11.9)Accounts receivable 0.6 — (2.1) (3.4)Other assets 6.5 4.3 (24.2) 3.3Accounts payable and accrued liabilities 4.8 0.3 1.4 (11.6)Income tax receivable / payable (0.3) (0.1) 0.8 2.6Uncertain tax position liabilities 27.2 56.6 88.1 171.1Other liabilities (4.6) (4.9) (13.1) (13.7)Proceeds received from insurance for operating expenses — — — 5.7Net cash provided by operating activities 74.4 76.4 183.3 213.6Cash flows from investing activitiesCapital expenditures (29.0) (16.6) (63.5) (53.4)Maturities of short-term investments — — — 60.0Cash disposed in deconsolidation transaction — — (58.4) —Purchase of intangible assets (40.0) — (40.0) —Other proceeds 0.3 1.5 5.1 12.9Other purchases and payments — 0.1 — (0.1)Net cash (used in) provided by investing activities (68.7) (15.0) (156.8) 19.4Cash flows from financing activitiesProceeds from long-term borrowings — — 60.7 —Payments on long-term borrowings (0.9) (2.0) (4.7) (7.5)Payments for debt issuance costs — — (1.3) —Other payments and distributions (2.5) (2.6) (7.8) (7.1)Payments for taxes related to net share settlement of equity awards (1.4) (0.2) (2.7) (0.5)Other proceeds 0.4 — 0.4 —Net cash (used in) provided by financing activities (4.4) (4.8) 44.7 (15.1)Net increase in cash and cash equivalents, and restricted cash 1.3 56.6 71.2 217.9Cash, cash equivalents, and restricted cash, beginning of period 325.4 401.0 255.5 239.7Cash, cash equivalents, and restricted cash, end of period $ 326.7 $ 457.6 $ 326.7 $ 457.6 The condensed consolidated statements of cash flows include continuing operations and discontinued operations for the periods pr Non-GAAP Financial Measures (Unaudited)
Page 5
Our management uses financial measures that are not in accordance with GAAP, in addition to financial measures in accordancewith GAAP to evaluate our operating results. These non-GAAP financial measures should be considered supplemental to, and nota substitute for, our reported financial results prepared in accordance with GAAP. EBITDA, adjusted EBITDA, EBITDA margin,adjusted EBITDA margin, adjusted net income (loss), adjusted net income (loss) per diluted share, and free cash flow arefinancial measures that are not defined under GAAP. Our management uses these non-GAAP financial measures and believesthey enhance an investor's understanding of our financial and operating performance from period to period because they excludecertain material non-cash items and certain other adjustments management believes are not reflective of our ongoing operationsand performance. These non-GAAP measures are not a measure of liquidity, cash generated by the Company, or cash availablefor discretionary expenditures. EBITDA is calculated as net income (loss) before net interest expense, interest income, income tax expense, depreciation andamortization; adjusted EBITDA is calculated as net income (loss) before net interest expense, interest income, income taxexpense, depreciation and amortization and also excludes certain contributions, such as cash expenditures related to campaignand political initiatives, items that we do not believe represent the operations of the core business such as cash and non-cashacquisition, disposition and specified transaction costs and certain other cash and non-cash costs including major system changes,impairments and disposals of long-lived assets including goodwill, discontinued operations, share-based compensation, otherincome and expense items, equity in net loss of Harvest and loss on Deconsolidation Transaction; EBITDA margin is calculatedas EBITDA as % of revenue; adjusted EBITDA margin is calculated as adjusted EBITDA as % of revenue; adjusted net income(loss) is calculated as net income (loss) less certain contributions, such as cash expenditures related to campaign and politicalinitiatives, items that we do not believe represent the operations of the core business such as cash and non-cash acquisition,disposition and specified transaction costs and certain other cash and non-cash costs including major system changes,impairments and disposals of long-lived assets including goodwill, discontinued operations, share-based compensation, otherincome and expense items, equity in net loss of Harvest and loss on Deconsolidation Transaction; adjusted EPS is calculated asadjusted net income (loss) divided by diluted shares outstanding; and free cash flow is calculated as cash flow from operationsless capital expenditures. Some of the items added back to, or removed from, these non-GAAP measures have occurred in priorperiods and may occur in future periods. We report these non-GAAP measures to help investors assess the operating performance of the Company's business. Thefinancial measures noted above are metrics that have been adjusted from GAAP net income (loss), net income (loss) per share,and cash flow from operating activities in an effort to provide readers with normalized metrics in making comparisons moremeaningful across the cannabis industry as competitors commonly disclose similar performance measures; however, ourcalculation of EBITDA, adjusted EBITDA, EBITDA margin, adjusted EBITDA margin, adjusted net income (loss), adjusted netincome (loss) per diluted share, and free cash flow may not be comparable to other similarly titled performance measures of othercompanies, as well as to remove items that may otherwise distort the GAAP net income (loss), net income (loss) per share orcash flow from operating activities measure. As noted above, our EBITDA, adjusted EBITDA, EBITDA margin, adjusted EBITDA margin, adjusted net income (loss),adjusted net income (loss) per diluted share, and free cash flow measures are not prepared in accordance with GAAP, and shouldnot be considered in isolation of, or as an alternative to, measures prepared in accordance with GAAP. There are a number oflimitations related to the use of these non-GAAP measures rather than net income (loss), net income (loss) per share and cashflow from operating activities, which are the most directly comparable financial measures calculated and presented in accordancewith GAAP. Because of these limitations, we consider, and you should consider, these non-GAAP measures together with otheroperating and financial performance measures presented in accordance with GAAP. A reconciliation of these non-GAAPmeasures to the most directly comparable financial measure calculated in accordance with GAAP can be found below. Reconciliation of Non-GAAP EBITDA and Adjusted EBITDA (Unaudited) The following table presents a reconciliation of GAAP net income (loss) attributable to common shareholders to non-GAAPEBITDA and Adjusted EBITDA for each of the periods presented: (Amounts expressed in millions of United States dollars) Three Months Ended For the Nine MSeptember30, 2026 September30, 2025 June 30,2026 September30, 2026Net income (loss) attributable to common shareholders $ 0.9 $ (26.8) $(406.0) $ (402.7)Add (deduct) impact of:Interest expense, net $ 12.0 $ 16.1 $ 12.8 $ 38.1Interest income $ (2.8) $ (4.4) $ (3.1) $ (8.6)Provision for income taxes $ 26.3 $ 53.0 $ 22.0 $ 70.1Depreciation and amortization $ 17.7 $ 29.5 $ 25.7 $ 73.2Depreciation included in cost of goods sold $ 12.3 $ 13.9 $ 13.4 $ 39.7EBITDA (Non-GAAP) $ 66.2 $ 81.3 $(335.2) $ (190.3)EBITDA Margin (Non-GAAP) 29 % 28 % NMF NMF (Gain) loss on disposal or impairment of assets $ (0.0) $ (0.9) $ 2.0 $ 1.7Campaign and political contributions $ 1.6 $ 6.3 $ 4.7 $ 15.9Acquisition, disposition and specified transaction costs $ 9.2 $ 3.8 $ 12.3 $ 28.9Share-based compensation $ 5.9 $ 5.8 $ 6.9 $ 17.0
Page 6
Other (income) expense, net $ (0.1) $ 1.2 $ (0.1) $ (0.4)Equity in net loss of Harvest $ 6.4 $ —$ 3.3 $ 9.7Loss on deconsolidation transaction $ — $ —$ 403.3 $ 403.3Discontinued operations, net of tax, attributable to common shareholders $ — $ 5.0 $ 0.7 $ 1.8Adjusted EBITDA (Non-GAAP) $ 89.2 $ 102.7 $ 98.0 $ 287.6Adjusted EBITDA Margin (Non-GAAP) 39 % 36 % 36 % 36 % NMF - No Meaningful Figure Reconciliation of Non-GAAP Adjusted Net Income (Loss) (Unaudited) The following table presents a reconciliation of GAAP net income (loss) attributable to common shareholders to non-GAAPadjusted net income (loss), for each of the periods presented: For the Three Months Ended For (Amounts expressed in millions of United States dollars) September30, 2026 September30, 2025 June 30,2026 Se3Net income (loss) attributable to common shareholders $ 0.9 $(26.8) $(406.0) $Net loss from discontinued operations, net of tax, attributable to common shareholders $ — $ 5.0 $ 0.7 $Net income (loss) from continuing operations available to common shareholders $ 0.9 $(21.8) $(405.3) $Add (deduct) impact of: (Gain) loss on disposal or impairment of assets $ (0.0) $ (0.9) $ 2.0 $Campaign and political contributions $ 1.6 $ 6.3 $ 4.7 $Acquisition, disposition and specified transaction costs $ 9.2 $ 3.8 $ 12.3 $Equity in net loss of Harvest $ 6.4 $ —$ 3.3 $Loss on deconsolidation transaction $ — $ —$403.3 $Adjusted net income (loss) (Non-GAAP) $ 18.0 $(12.5) $ 20.4 $ Reconciliation of Non-GAAP Adjusted Net Income (Loss) Per Diluted Share (Unaudited) The following table presents a reconciliation of GAAP net income (loss) attributable to common shareholders per share to non-GAAP adjusted net income (loss) per diluted share, for each of the periods presented: For the Three Months Ended For (Amounts expressed are per share except for shares which are in millions) September30, 2026 September30, 2025 June 30,2026 Sep30Net income (loss) attributable to common shareholders $ 0.00 $(0.14) $(2.11) $Net loss from discontinued operations, net of tax, attributable to common shareholders$ — $ 0.03 $0.00 $Net income (loss) from continuing operations available to common shareholders $ 0.00 $ (0.11) $(2.10) $Add (deduct) impact of: (Gain) loss on disposal or impairment of assets $(0.00) $(0.00) $0.01 $Campaign and political contributions $ 0.01 $ 0.03 $0.02 $Acquisition, disposition and specified transaction costs $ 0.05 $ 0.02 $0.06 $Equity in net loss of Harvest $ 0.03 $ —$0.02 $Loss on deconsolidation transaction $ — $ —$2.09 $Adjusted net income (loss) (Non-GAAP) $ 0.09 $(0.07) $0.11 $Diluted shares outstanding 200.6 191.2 192.7 Reconciliation of Non-GAAP Free Cash Flow (Unaudited) The following table presents a reconciliation of GAAP cash flow from operating activities to non-GAAP free cash flow, for eachof the periods presented: For the Three Months Ended For the Nine Months Ended (Amounts expressed in millions of United States dollars) September30, 2026 September30, 2025 June 30,2026 September30, 2026 September30, 2025Cash flow from operating activities $ 74.4 $ 76.4 $53.1 $ 183.3 $ 213.6Capital expenditures $ (29.0) $ (16.6) $(21.0) $ (63.5) $ (53.4)Free cash flow (Non-GAAP) $ 45.4 $ 59.8 $32.1 $ 119.8 $ 160.2 Forward-Looking Statements This news release includes forward-looking information and statements within the meaning of the U.S. Private SecuritiesLitigation Reform Act of 1995 and applicable Canadian securities legislation (collectively herein referred to as "forward-lookingstatements"). These forward-looking statements relate to the Company's expectations or forecasts of business, operations,
Page 7
financial performance, cash flows, prospects, and other plans, intentions, expectations, estimates, and beliefs and includestatements regarding broader cannabis rescheduling and state program expansion. Words such as "expects", "continue", "will","anticipates" and "intends" or similar expressions are intended to identify forward-looking statements. These forward-lookingstatements are based on the Company's current projections and expectations about future events and financial trends thatmanagement believes might affect its financial condition, results of operations, business strategy and financial needs, and oncertain assumptions and analysis made by the Company in light of the experience and perception of historical trends, currentconditions and expected future developments and other factors management believes are appropriate. Forward-lookingstatements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which maycause actual events, results, performance, or achievements of the Company to be materially different from future events, results,performance, and achievements expressed or implied by forward-looking statements herein, including, without limitation, therisks discussed under the heading "Risk Factors" in our most recent Annual Report on Form 10-K and in our periodic reportssubsequently filed with the United States Securities and Exchange Commission and in the Company's filings onhttps://www.sedarplus.ca. Although the Company believes that any forward-looking statements herein are reasonable, in light ofthe use of assumptions and the significant risks and uncertainties inherent in such statements, there can be no assurance that anysuch forward-looking statements will prove to be accurate, and accordingly readers are advised to rely on their own evaluation ofsuch risks and uncertainties and should not place undue reliance upon such forward-looking statements. Any forward-lookingstatements herein are made as of the date hereof and, except as required by applicable laws, the Company assumes no obligationand disclaims any intention to update or revise any forward-looking statements herein or to update the reasons that actual eventsor results could or do differ from those projected in any forward-looking statements herein, whether as a result of newinformation, future events or results, or otherwise. About Trulieve Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S., with establishedmedical marijuana operations in Florida, Georgia, Pennsylvania, and West Virginia. Driven by a core mission to expand access tocannabis, Trulieve serves customers with innovative, high-quality branded products and exceptional experiences. With scaledoperations in attractive markets and targeted expansion through its hub strategy, Trulieve is poised for accelerated growth.Trulieve is listed on the NYSE under the symbol TRLV. For more information, please visit Trulieve.com. Facebook: @TrulieveInstagram: @TrulieveX: @Trulieve Investor and Media Contact Christine Hersey, Chief Corporate Affairs & Strategy Officer+1 (424) 202-0210Christine.Hersey@Trulieve.com SOURCE Trulieve Cannabis Corp. https://investors.trulieve.com/2026-11-05-Trulieve-Reports-Third-Quarter-2026-Results